The Burning Antecubital Fossa
Mr. R is a 58-year-old outpatient scheduled for a contrast-enhanced liver MRI to characterize a 2.4 cm segment VII lesion seen on ultrasound. His chart lists an eGFR of 36 mL/min/1.73 m² from labs drawn five months ago; he has type 2 diabetes and hypertension. A 22-gauge IV is placed in the right antecubital fossa and flushes without resistance. The power injector is set to deliver 10 mL of a macrocyclic agent at 2 mL/s. About 4 mL in, Mr. R says the site "burns," and the technologist sees the antecubital area beginning to swell. The injection is stopped. There is no other IV in place, and the radiologist still wants contrast to answer the question.
1. What are your immediate actions at the table, and what findings would push this from a routine extravasation to a same-day surgical referral?
Read the worked answer
Immediately:
- Disarm/disconnect the injector so no residual pressure can deliver more volume; do not flush the line.
- Leave the cannula in place until the patient is evaluated, then remove it (follow departmental policy on gentle aspiration before removal).
- Elevate the arm above heart level, apply a cold compress, and examine the site: measure and mark the border of the swelling with a skin marker so progression can be tracked.
- Notify the radiologist and document the volume delivered versus intended.
Escalation triggers (department policies vary, but reasons consistently):
- Large volume (commonly >10 mL, or a substantial fraction of the intended dose), a tense/firm compartment, blistering, or skin discoloration.
- Neurovascular compromise: numbness, weakness, loss of distal pulse, capillary refill >3 seconds, or pain out of proportion that worsens rather than settles.
- Failure of the swelling to improve over the observation period.
Those findings warrant same-day surgical/plastic surgery evaluation. A small, soft, non-tender swelling with intact distal neurovascular status is managed conservatively with elevation, icing, and 24-hour telephone follow-up.
2. The study still needs contrast. How do you decide whether to proceed, and what do you do about the five-month-old eGFR of 36?
Read the worked answer
Two separate questions: access and renal risk.
Access: Do not reuse the infiltrated site. Start a new IV in the contralateral arm (or another suitable vein), confirm brisk blood return and a saline flush without resistance or pain, and use a rate the vein tolerates. A 22-gauge in a good antecubital vein is acceptable for 2 mL/s; a smaller or more distal vein argues for a slower rate.
Renal risk: eGFR 36 is CKD 3b, and the labs are older than the 3-month window many policies use for stable outpatients. Because he has diabetes and hypertension, repeat a creatinine if it will not meaningfully delay an indicated study. Regardless: a single standard dose of a group II (macrocyclic) agent is generally acceptable at eGFR ≥30, and dialysis is not required. If the repeat value is <30 or the patient has acute kidney injury, the study becomes a risk–benefit discussion with the radiologist - options include deferring contrast, using a hepatobiliary agent if the clinical question fits, or answering the question with a noncontrast liver protocol (DWI, T2, and unenhanced dynamic sequences) plus short-interval follow-up.
The decision rule is: confirm the vein works, confirm the renal data are current enough, then give the smallest dose of a group II agent that answers the question.
3. What documentation and follow-up close this out, and what would you write about the delayed scan?
Read the worked answer
- Contrast agent, concentration, volume delivered vs. intended, flow rate, IV site, gauge, and the exact time of the event.
- Objective description of the site (size, tenderness, color, distal pulses, sensation) at the time of injury and at each recheck.
- Name of the radiologist notified and the disposition (proceeded, deferred, or referred).
- Patient instructions in writing: elevate, ice, and return or call immediately for increasing pain, blistering, numbness, or skin changes.
- A documented 24-hour follow-up call, plus an internal occurrence report so the event can be trended.
- If contrast was ultimately administered from a new site and the images are diagnostic, say so; if the question remains unanswered because of degraded or delayed technique, note the limitation and the recommended next step (repeat study, alternative imaging) so the referring clinician is not left assuming a negative study.
- If the eGFR was outdated and not repeated, note that in the report as a data limitation.